We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Pfizer is a member of our Medical group, which includes 908 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. PFE is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for PFE's full-year earnings has moved 1.50% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that PFE has returned about 0.79% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 0.76% on average. This shows that Pfizer is outperforming its peers so far this year.
Looking more specifically, PFE belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #48 in the Zacks Industry Rank. Stocks in this group have gained about 0.45% so far this year, so PFE is performing better this group in terms of year-to-date returns.
PFE will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Pfizer is a member of our Medical group, which includes 908 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. PFE is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for PFE's full-year earnings has moved 1.50% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that PFE has returned about 0.79% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 0.76% on average. This shows that Pfizer is outperforming its peers so far this year.
Looking more specifically, PFE belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #48 in the Zacks Industry Rank. Stocks in this group have gained about 0.45% so far this year, so PFE is performing better this group in terms of year-to-date returns.
PFE will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.